ATS 2026 guideline covers as-needed inhaled corticosteroids in asthma
Guideline Central said the American Thoracic Society guideline highlights key recommendations on two reliever strategies combining inhaled corticosteroids with either a short-acting beta2-agonist or formoterol.
“highlighting key recommendations across inhaled corticosteroid–short-acting beta2-agonist and inhaled corticosteroid–formoterol reliever strategies”— Guideline Central
Guideline Central, which describes itself as providing healthcare professionals with evidence-based clinical decision support tools and current guidelines, has drawn attention to a 2026 American Thoracic Society (ATS) guideline on as-needed inhaled corticosteroids in asthma.
In a post on X on 14 November 2026, the account said the guideline highlights key recommendations across two reliever strategies: inhaled corticosteroid–short-acting beta2-agonist and inhaled corticosteroid–formoterol.
The post does not set out the individual recommendations, their strength or the evidence behind them. It includes a link to further material. According to its profile, Guideline Central is partnered with 45 or more medical associations.
Original source
“highlighting key recommendations across inhaled corticosteroid–short-acting beta2-agonist and inhaled corticosteroid–formoterol reliever strategies”
— Guideline Central View the post on X